$The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients$

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients

Graham F Pineo1, Jay Lin2, Lieven Annemans31Department of Medicine, University of Calgary, Calgary, Alberta, Canada; 2Novosys Health, Flemington, NJ; 3Department of Medicine, Ghent University, Ghent and Brussels University, Brussels, BelgiumAbstract: Venous thromboembolism (VTE) is a common complica...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Pineo GF, Lin J, Annemans L
Format:	Artykuł
Język:	English
Wydane:	Dove Medical Press 2012-04-01
Seria:	ClinicoEconomics and Outcomes Research
Dostęp online:	http://www.dovepress.com/the-economic-impact-of-enoxaparin-versus-unfractionated-heparin-for-pr-a9748

Podobne zapisy

Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight
od: David Michael Kaylor PharmD, i wsp.
Wydane: (2023-02-01)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
od: Joseph Lewis BA, i wsp.
Wydane: (2022-05-01)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
od: Thompson David, i wsp.
Wydane: (2006-09-01)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
od: Alpesh Amin, i wsp.
Wydane: (2023-06-01)

PHARMACO-ECONOMIC COMPARISON OF ENOXAPARIN AND UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION
od: A. V. Syrov, i wsp.
Wydane: (2010-04-01)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
od: Milne Ruairidh, i wsp.
Wydane: (2001-10-01)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
od: Fakiha Siddiqui BDS, i wsp.
Wydane: (2020-01-01)

Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery
od: Luminita Iliuta, i wsp.
Wydane: (2022-08-01)

Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy
od: Oleksandr Oliynyk, i wsp.
Wydane: (2021-09-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
od: Hosein Vakili, i wsp.
Wydane: (2007-04-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
od: Hosein Vakili, i wsp.
Wydane: (2007-07-01)

Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention
od: Zhi-Zhong Li, i wsp.
Wydane: (2018-01-01)

Heparin versus enoxaparine for prevention of asymptomatic deep venous thrombosis after total knee arthroplasty
od: Adnan H. Hnoosh, i wsp.
Wydane: (2013-01-01)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
od: Lily Nguyen, i wsp.
Wydane: (2023-08-01)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
od: Khalid Al Sulaiman, i wsp.
Wydane: (2022-12-01)

Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report
od: Aslan Efendizade, i wsp.
Wydane: (2020-09-01)

Comparison of Intravenous Enoxaparin with Subcutaneous Enoxaparin in Preventing Venous Thromboembolism in Patients Admitted to Intensive Care Unit
od: Masoum Khoshfetrat, i wsp.
Wydane: (2020-05-01)

Safety and efficacy of low-molecular-weight heparin in patients with acute venous thromboembolism postthrombolytic therapy as compared to unfractionated heparin: A systematic review and meta-analysis
od: Eman M. Mansory, i wsp.
Wydane: (2024-12-01)

Prevention of venous thromboembolic events in ischemic stroke
od: Vladimir Anatolyevich Parfenov
Wydane: (2013-11-01)

Heparin versus Danaproid for Prevention of Venous Thromboembolism after Hip Surgery
od: J Nakase, i wsp.
Wydane: (2009-04-01)

The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?
od: Pieter M.M. De Kesel, i wsp.
Wydane: (2020-01-01)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
od: Javier Trujillo‐Santos, i wsp.
Wydane: (2022-05-01)

Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure
od: Alpesh N. Amin, i wsp.
Wydane: (2024-02-01)

Intravenous thrombolysis in acute ischemic stroke after antagonization of unfractionated heparin with protamine: case series and systematic review of literature
od: Katharina Kneer, i wsp.
Wydane: (2023-01-01)

Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial
od: Ahmad Mirdamadi, i wsp.
Wydane: (2014-11-01)

Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides.
od: Navin K Kapur, i wsp.
Wydane: (2012-01-01)

Delayed prophylaxis with unfractionated heparin increases the risk of venous thromboembolic events in patients with moderate to severe traumatic brain injury: a retrospective analysis
od: Giovanna Brandi, i wsp.
Wydane: (2020-03-01)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
od: Aliya Abdulla, i wsp.
Wydane: (2023-02-01)

Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center
od: Victoria Diamond, i wsp.
Wydane: (2024-12-01)

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial
od: Chadli Dziri, i wsp.
Wydane: (2023-01-01)

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
od: Chadli Dziri, i wsp.
Wydane: (2023-01-01)

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
od: Levitan B, i wsp.
Wydane: (2014-03-01)

Bemiparin Versus Enoxaparin for Extended Thromboprophylaxis in COVID-19 Patients at High Risk of Venous Thromboembolism
od: Ahmet Can TOPÇU, i wsp.
Wydane: (2021-01-01)

Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention
od: Ji Huang, i wsp.
Wydane: (2018-01-01)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
od: Craig D. Seaman, i wsp.
Wydane: (2020-11-01)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
od: Flávio Luís Garcia, i wsp.
Wydane: (2015-08-01)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
od: Sake J. van der Wall, i wsp.
Wydane: (2018-02-01)

COST- EFFECTIVENESS ANALYSIS OF APIXABANO VS. ENOXAPARIN IN THE THROMBOEMBOLISM IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ARTHROPLASTY ELECTIVE THE HIP OR KNEE
od: Óscar Lourenço, i wsp.
Wydane: (2012-12-01)

The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility
od: Kogenta Nakamura, i wsp.
Wydane: (2007-06-01)

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
od: Daniel Dybdahl, i wsp.
Wydane: (2019-07-01)